Oneiric (Sleep) Disorder – REM Behavior Disorder (RBD)

Overview

Oneiric disorder, more commonly called REM (Rapid Eye Movement) Behavior Disorder (RBD), is a parasomnia in which the normal muscle atonia (paralysis) that characterizes REM sleep is absent. As a result, people act out vivid dreams—sometimes violently—by shouting, flailing, punching, or even jumping out of bed.

RBD is most frequently diagnosed in middle‑aged and older adults, especially men. It is estimated to affect 0.5 %–2 % of the general adult population, but prevalence rises to **5 %–15 % in adults over 65** and is even higher among patients with neurodegenerative diseases such as Parkinson’s disease (PD) and Lewy body dementia (LBD) (Mayo Clinic).

Symptoms

Symptoms of RBD usually begin gradually and may be intermittent at first. The full symptom list includes:

• Vivid, action‑filled dreams—often themed around fighting, running, or sexual activity.
• Physical enactment of dreams—shouting, screaming, punching, kicking, or flailing limbs during REM sleep.
• Sudden awakenings with confusion—often with a sense of “being attacked” or “being chased.”
• Injury to self or bed partner—bruises, cuts, broken bones, or dental trauma.
• Sleep disruption—frequent awakenings, excessive daytime sleepiness, or non‑restorative sleep.
• Auditory phenomena—loud vocalizations, shouting, or screaming.
• Motor activity without loss of consciousness—the person remains aware of the environment while acting out dreams.
• Absence of “normal” REM atonia on polysomnography—the defining objective finding.
• Co‑existing sleep disorders—obstructive sleep apnea (OSA), periodic limb movement disorder (PLMD), or insomnia.

Causes and Risk Factors

Primary (Idiopathic) RBD

In ~70 % of cases the cause is unknown—termed idiopathic RBD. However, longitudinal studies show that 30 %–50 % of individuals with idiopathic RBD later develop a neurodegenerative disease, most commonly synucleinopathies (PD, LBD, multiple system atrophy).

Secondary RBD

RBD can be triggered by an underlying condition that disrupts the brainstem regions responsible for REM atonia:

• Neurodegenerative diseases (Parkinson’s, Lewy body dementia, multiple system atrophy)
• Brainstem lesions (stroke, tumor, trauma)
• Use of certain medications (e.g., antidepressants—especially SSRIs, SNRIs, tricyclics; β‑blockers; antipsychotics)
• Withdrawal from alcohol or sedative‑hypnotics
• Other sleep disorders (narcolepsy, OSA)

Risk Factors

• Age: Risk rises sharply after age 50.
• Sex: ~80 % of diagnosed patients are male.
• Family history: First‑degree relatives have a higher likelihood, suggesting a genetic component.
• Medication exposure: Antidepressants are the most common drug‑related precipitant.
• Co‑existing neurodegenerative disease: Presence of PD, LBD, or MSA dramatically increases risk.

Diagnosis

Diagnosing RBD relies on a combination of clinical history, bedside observation, and objective sleep testing.

Clinical Evaluation

• Detailed sleep history—patient and bed partner describe dream content and behaviors.
• Screen for injuries, daytime sleepiness, and other parasomnias.
• Medication review to identify potential triggers.

Polysomnography (PSG)

The gold‑standard test. Overnight video PSG records brain waves (EEG), eye movements (EOG), muscle activity (EMG), heart rhythm, and breathing.

• During REM sleep, EMG activity > 30 % of the total REM period indicates loss of atonia.
• Video captures the physical behaviors that correlate with EMG spikes.

Questionnaires

• RBD Screening Questionnaire (RBD‑SQ) – useful for primary‑care settings.
• International Restless Legs Syndrome Study Group (IRLSSG) questionnaire – to rule out PLMD.

Additional Tests (when indicated)

• Brain MRI – to exclude structural lesions.
• DaT‑SPECT imaging – may reveal dopaminergic deficits in patients at risk for Parkinsonism.
• Neuropsychological testing – if cognitive decline is suspected.

Treatment Options

Pharmacologic Therapy

• Clonazepam (0.5–2 mg at bedtime) – First‑line medication; reduces motor activity in > 80 % of patients (Cleveland Clinic).
• Melatonin (3–12 mg nightly) – Effective for many, especially those who cannot tolerate clonazepam; has a favorable safety profile.
• Alternative agents – Doxepin, pramipexole, or levodopa may be used in refractory cases, though data are limited.

Safety Measures (non‑pharmacologic)

• Place a padded mattress or place the bed on the floor.
• Remove sharp objects, furniture edges, and clutter from the bedroom.
• Use a bed rail** or low‑profile side rails** if the patient shares a bed.
• Consider a partner’s protective gear (e.g., mouth guard) if dental injury occurs.